The renin-angiotensin system and the long-term complications of diabetes: Pathophysiological and therapeutic considerations

Diabetic Medicine

Volumn 20, Issue 8, 2003, Pages 607-621

  Gilbert, Richard E ^a   Krum, H ^b   Wilkinson Berka, J ^b   Kelly, D J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin II; Ischaemia; Nephropathies; Retinopathy; Transforming growth factor beta; Vascular endothelial growth factor

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; GROWTH FACTOR; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; RAMIPRIL; RENIN; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VALSARTAN;

ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; ENZYME INHIBITION; EYE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEART; HEART FAILURE; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; KIDNEY INJURY; MEDIATOR; META ANALYSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE INJURY; TRANSGENIC ANIMAL;

ANGIOTENSIN II; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; GROWTH SUBSTANCES; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0042134568     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00979.x     Document Type: Review

References (176)

1. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808.
2. Ferris FL, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999; 341: 667-678.
3. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-4245.
4. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE. A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology 1987; 120: 2334-2338.
5. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int 1997; 52: S107-S110.
6. Christlieb AR. Renin-angiotensin-aldosterone system in diabetes mellitus. Diabetes 1976; 25: 820-825.
7. Ardaillou R, Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int 1997; 52: 1458-1468.
8. de Gasparo M, Bullock GR. The AT1 and AT2 angiotensin II receptors. In Oparil S, Weber MA eds. Hypertension: A Companion to Brenner and Rector's The Kidney. St Louis: W. B. Saunders, 2000; 100-110.
9. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y et al. Angiotensin AT (1) and AT (2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001; 88: 22-29.
10. Flyvberg A, Grønbæk H, Christainsen T, Bak M, Nielsen B, Vogel I et al. The role of growth factors in the renal complications of diabetes. In Marshall SM, Rizza RA eds. The Diabetes Annual/11. Amsterdam: Elsevier Science B. V. 1998.
11. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
12. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999; 48: 1899-1906.
13. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin Ii in renal fibrosis. Hypertension 1998; 31: 181-188.
14. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+) AC133(+) endothelial precursor cells. Circ Res 2001; 88: 167-174.
15. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int 1994; 45: 612-622.
16. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187: 251-259.
17. Border WA, Yamamoto T, Noble NA. Transforming growth factor-β in diabetic nephropathy. Diabetes/Metab Rev 1996; 12: 309-339.
18. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK. Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995; 48: 1818-1827.
19. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93: 536-542.
20. Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Kidney Int Suppl 1998; 68: S41-45.
21. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42: 450-456.
22. Park I-S, Kiyomoto H, Abboud SL, Abboud HE. Expression of transforming growth factor-β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997; 46: 473-480.
23. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen L, Jerums G et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes 1998; 47: 414-422.
24. Fukui M, Nakamura T, Ebihara I, Makita Y, Osada S, Tomino Y et al. Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli. J Lab Clin Med 1994; 123: 763-768.
25. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818.
26. Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y et al. Quantification of glomerular TGF-beta-1 mRNA in patients with diabetes mellitus. Kidney Int 1996; 49: 1120-1126.
27. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BRC et al. Increased renal production of transforming growth factor-β1 in patients with type II diabetes. Diabetes 1997; 46: 854-859.
28. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
29. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R et al. Captopril-induced reduction of serum levels of transforming growth factor-beta 1 correlates with long-term renoprotection in insulin-dependent diabetic patients [published erratum appears in Am J Kidney Dis 2000 March; 35: 572]. Am J Kidney Dis 1999; 34: 818-823.
30. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002; 25: 1072-1077.
31. Aiello LP, Pierce EA, Foley ED, Takagi H, Chert H, Riddle L et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothehal growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
32. Senger DR, Connolly DT, Van De Water L, Feder J, Dvorak HF. Purification and NH-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-1778.
33. Adamis AP, Miller JW, Bernal MT, Damico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450.
34. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
35. Gilbert RE, Vranes D, Wilkinson-Berka JL, Cox A, Wu LL, Stacker S. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998; 78: 1017-1027.
36. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin Ii increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25: 913-917.
37. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619-628.
38. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43: 1360-1367.
39. Chaturvedi N, Sjohe A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
40. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat. Kidney Int 1998; 54: 343-352.
41. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344: 541-544.
42. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 2000; 57: 1882-1894.
43. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
44. Strojek K, Grzeszczak W, Morawin E, Adamski M, Lacka B, Rudzki H et al. Nephropathy of type II diabetes: evidence for hereditary factors? Kidney Int 1997; 51: 1602-1607.
45. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
46. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43: 384-388.
47. Parring H-H, Tarnow L, Rossing P. Genetics of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 2509-2517.
48. Schmidt S, Ritz E. Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant 1997; 12: 37-41.
49. McLaughlin KJ, Harden PN, Ueda S, Boulton-Jones JM, Connell JM, Jardine AG. The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases. Hypertension 1996; 28: 912-915.
50. Navar LG, Lewis L, Hymel A, Braam B, Mitchell KD. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J Am Soc Nephrol 1994; 5: 1153-1158.
51. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Seminars Nephrol 1997; 17: 412-422.
52. Moe OW, Alpern RJ, Henrich WL. The renal proximal tubule renin-angiotensin system. Seminars Nephrol 1993; 13: 552-557.
53. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI et al. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy - implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999; 155: 429-440.
54. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999; 48: 2066-2073.
55. Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JSD. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999; 55: 454-464.
56. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23: 647-655.
57. Anderson S, Rennke H, Brenner B. Therapeutic advantages of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
58. Zatz R, Dunn BR, Meyer TW, Brenner B. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
59. Bohrer MP, Deen WM, Robertson CR, Brenner BM. Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol 1977; 233: F13-21.
60. Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000; 58: 2129-2137.
61. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
62. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 870-873.
63. Langham RG, Kelly DJ, Cox A, Holthöfer H, Zaoui P, Pinel N et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002; 45: 1572-1576.
64. Kelly DJ, Aaltonen P, Cox AJ, Rumble JR, Langham R, Panagiotopoulos S et al. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of antiproteinuric therapies. Nephrol Dial Transplant 2002; 17: 1327-1332.
65. Jerums G, Panagiotopoulos S, Tsalamandris C, Allen TJ, Gilbert RE, Comper WD. Why is proteinuria such an important risk factor for progression in clinical trials. Kidney Int 1997; S87-S92.
66. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.
67. Cordonnier DJ, Pinel N, Barro C, Maynard C, Zaoui P, Halimi S et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999; 10: 1253-1263.
68. Nikolic-Paterson DJ, Lan HY, Hill PA, Atkins RC. Macrophages in renal injury. Kidney Int Suppl 1994; 45: 879-82.
69. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58: 1492-1499.
70. Ruiz-Ortega M, Bustos C, Hernandezpresa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin ii participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa-B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998; 161: 430-439.
71. Ricardo SD, Franzoni DF, Roesener CD, Crisman JM, Diamond JR. Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells. Am J Physiol - Renal Fluid Electrolyte Physiol 2000; 278: F708-F716.
72. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997; 100: 1047-1058.
73. Hahn AWA, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Letters 1994; 347: 178-180.
74. Foris G, Dezso B, Medgyesi GA, Fust G. Effect of angiotensin II on macrophage functions. Immunology 1983; 48: 529-535.
75. Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC et al. Macrophage and myofibroblast proliferation in remnant kidney: role of angiotensin II. Kidney Int 1997; 52: S221-S225.
76. Kelly DJ, Wilkinson-Berka JL, Ricardo SD, Cox AJ, Gilbert RE. Osteopontin expression and macrophage accumulation in advanced diabetic nephropathy. Nephrol Dialysis Transplantation 2002; 17: 1-7.
77. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986; 293: 471-474.
78. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 339-343.
79. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000; 23: 1725-1730.
80. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995; 99: 497-504.
81. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319: 24-25.
82. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998; 21: 104-110.
83. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37: 890-899.
84. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nepbropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
85. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
86. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.
87. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes: a 7 year follow-up study. Arch Int Med 1996; 156: 286-289.
88. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222.
89. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23: B54-64.
90. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
91. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
92. The Cardiac Insufficiency Bisoprolol Study II. CIBIS-II: a randomised trial. Lancet 1999; 353: 9-13.
93. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
94. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. Br Med J 2000; 321: 1440-1444.
95. Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T et al. Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420-424.
96. Epstein M, Buckalew V, Martinez F, on behalf of the eplerenone 021 investigators. Anti-proteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002; 15(Suppl. 1): 24A.
97. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982-988.
98. Ruggenenti P, Remuzzi G. Primary prevention of renal failure in diabetic patients - the Bergamo Nephrologic Diabetes Complication Trial. J Hypertens 1998; 16: S95-S97.
99. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.
100. Taft J, Nolan CJ, Yeung SP, Hewitson TD, Martin FIR. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-1051.
101. Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FI. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 1998; 47: 12-15.
102. ESPRIT. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes 2001; 50: 843-850.
103. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85: 643-650.
104. Danser AHJ, Saris JJ, Schuijt MP, van Kats JP. Is there a local renin-angiotensin system in the heart? Cardiovascular Res 1999; 44: 252-265.
105. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-1281.
106. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A et al. Myocyte death in streprozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest 2000; 80: 513-527.
107. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A et al. Myocardial cell death in human diabetes. Circ Res 2000; 87: 1123-1132.
108. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998; 101: 1326-1342.
109. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-1724.
110. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-1446.
111. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34.
112. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999; 20: 789-795.
113. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999; 34: 83-89.
114. Ryden L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21: 1967-78.
115. HOPE. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
116. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
117. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
118. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
119. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
120. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
121. Campbell DJ, Aggarwal A, Esler M, Kaye D. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001; 358: 1609-1610.
122. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R et al. Effect of carvedilol on left ventricular dysfunction and mortality in diabetic versus non-diabetic patients with isachemic or non-ischaemic dilated cardiomyopathy. Circulation 1996; 94: I664A.
123. Dzau VJ, Burt DW, Pratt RE. Molecular biology of the renin-angiotensin system. Am J Physiol 1988; 255: F563-573.
124. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-1378.
125. Hoshida S, Kato J, Nishino M, Egami Y, Takeda T, Kawabata M et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 2001; 103: 630-633.
126. Laine P, Kaartinen M, Penttilä A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999; 99: 361-369.
127. Gilbert RE, Rumble JR, Cao ZM, Cox AJ, van Eeden P, Allen TJ et al. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circulation Res 2000; 86: 158-165.
128. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-188.
129. Vaughan DE. AT(1) receptor blockade and atherosclerosis: hopeful insights into vascular protection. Circulation 2000; 101: 1496-1497.
130. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586-1593.
131. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-959.
132. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
133. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
134. Rumble JR, Gilbert RE, Cox A, Wu L, Cooper ME. Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta(1) and type IV collagen in diabetic vasculopathy. J Hypertension 1998; 16: 1603-1609.
135. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
136. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77: 1017-1020.
137. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
138. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford SL, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
139. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
140. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Br Med J 1998; 317: 713-720.
141. Cutler JA. Calcium-channel blockers for hypertension - uncertainty continues. N Engl J Med 1998; 338: 679-681.
142. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
143. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.
144. Hannson L. STOP-Hypertension-2 and best practice for the future. Heart 2000; 84: i2-4: discussion i50.
145. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412-419.
146. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
147. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9: 342-360.
148. Passa P, Chatellier G. The DIAB-HYCAR Study. Diabetologia 1996; 39: 1662-1667.
149. Wilkinson-Berka JL, Kelly DJ, Gilbert RE. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. J Vase Res 2001; 38: 527-535.
150. Luetscher LA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. New Engl J Med 1985; 312: 1412.
151. Schalekamp MADH. Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease. Clin Invest 1993; 71: S3-S6.
152. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-679.
153. Sasaki KI, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002; 109: 603-611.
154. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B2 receptor pathway. Circ Res 2001; 89: 678-683.
155. Machado RDP, Santos RAS, Andrade SP. Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am J Physiol 2001; 280: R994-1000.
156. Celerier J, Cruz A, Lamande N, Gasc JM, Corvol P. Angiotensinogen and
157. Otani A, Takagi H, Oh H, Koyama S, Honda Y. Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 2001; 50: 867-875.
158. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099-1104.
159. Chaturvedi N. Modulation of the renin-angiotensin system and retinopathy. Heart 2000; 84: i29-31.
160. Larsen M, Hommel E, Parving H-H, Lund-Andersen H. Protective effects of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 505-509.
161. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993; 25: 284-289.
162. Sjølie A. The diabetic retinopathy candesartan trial (DIRECT) Programme. J Renin-Angiotensin Aldosterone System 2001; 2: 28 (Abstract).
163. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50: 684-692.
164. Hollenberg NK. ACE inhibitors, AT1 receptor blockers, and the kidney. Nephrol Dial Transplant 1997; 12: 381-383.
165. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
166. Allen TJ, Cao ZM, Youssef S, Hulthen UL, Cooper ME. Role of angiotensin Ii and bradykinin in experimental diabetic nephropathy - functional and structural studies. Diabetes 1997; 46: 1612-1618.
167. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762-769.
168. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606.
169. Plat F, Saini R. Management of hypertension - the role of combination therapy. Am J Hypertens 1997; 10: S262-S271.
170. Hebert LA, Falkenhain ME, Nahman NS, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19: 1-6.
171. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851-856.
172. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
173. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-992.
174. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223-1229.
175. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999; 84: 1043-1049.
176. Hahn AW, Kern F, Buhler FR, Resink TJ. The renin-angiotensin system and extracellular matrix. Clin Invest 1993; 71: S7-12.